A Vision for Gastrin-Releasing Peptide Receptor Targeting for Imaging and Therapy: Perspective from Academia and Industry

The gastrin-releasing peptide receptor (GRPR) is overexpressed in various cancers, including prostate cancer, breast cancer, small cell and non-small cell lung cancer, uterine and ovarian cancer, colon cancer, and gastrointestinal stromal tumors. This makes GRPR a multicancer target for theranostics...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of nuclear medicine (1978) Jg. 66; H. 8; S. 1160
Hauptverfasser: Morgat, Clément, Duan, Heying, Dalm, Simone, Hindié, Elif, Günther, Thomas, Krause, Bernd J, Kramer, Vasko, Cavelier, Florine, Stephens, Andrew W, Moran, Stephen, Lamb, Laura, Iagaru, Andrei
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.08.2025
Schlagworte:
Academia
Animals
Humans
Molecular Imaging - methods
Molecular Targeted Therapy
Neoplasms - diagnostic imaging
Neoplasms - metabolism
Neoplasms - therapy
Receptors, Bombesin - metabolism
breast cancer
prostate cancer
GRPR
PET
ISSN:1535-5667, 1535-5667
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The gastrin-releasing peptide receptor (GRPR) is overexpressed in various cancers, including prostate cancer, breast cancer, small cell and non-small cell lung cancer, uterine and ovarian cancer, colon cancer, and gastrointestinal stromal tumors. This makes GRPR a multicancer target for theranostics, that is, molecular imaging and therapy. Here, we explore the current state of GRPR-targeted theranostics from bench to bedside, highlighting the preclinical development of various GRPR-targeting compounds and clinical applications. We review the role of GRPR-targeted molecular imaging for all stages of prostate cancer, breast cancer, and other tumors and provide a quo vadis GRPR. We aimed to offer a comprehensive overview of GRPR-targeted theranostics to inform researchers, clinicians, pharma, and regulators of the potential benefits and emerging opportunities in the pursuit of personalized precision cancer care.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1535-5667
1535-5667
DOI:10.2967/jnumed.124.269444